Kercheville Advisors LLC Sells 1,200 Shares of Novo Nordisk A/S (NYSE:NVO)

Kercheville Advisors LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 18.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,250 shares of the company’s stock after selling 1,200 shares during the period. Kercheville Advisors LLC’s holdings in Novo Nordisk A/S were worth $452,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC increased its stake in Novo Nordisk A/S by 110.5% in the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after buying an additional 9,012 shares in the last quarter. Mather Group LLC. grew its position in shares of Novo Nordisk A/S by 4.3% during the third quarter. Mather Group LLC. now owns 5,835 shares of the company’s stock valued at $695,000 after purchasing an additional 243 shares in the last quarter. Park Place Capital Corp purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at about $119,000. Olistico Wealth LLC grew its position in shares of Novo Nordisk A/S by 6.3% during the third quarter. Olistico Wealth LLC now owns 7,731 shares of the company’s stock valued at $921,000 after purchasing an additional 460 shares in the last quarter. Finally, Gratus Wealth Advisors LLC grew its position in shares of Novo Nordisk A/S by 69.0% during the third quarter. Gratus Wealth Advisors LLC now owns 3,693 shares of the company’s stock valued at $435,000 after purchasing an additional 1,508 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $85.83 on Thursday. The firm’s fifty day simple moving average is $92.65 and its two-hundred day simple moving average is $112.19. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The firm has a market capitalization of $385.16 billion, a P/E ratio of 27.78, a P/E/G ratio of 0.93 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. Analysts forecast that Novo Nordisk A/S will post 3.16 EPS for the current fiscal year.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.